Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume51Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; 4Creativ Research SAS, Paris, France; 5Global Evidence and Value Development, Sanofi-Aventis, Paris, FranceObjective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Nethe... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2011 |
Reihe/Periodikum: | Neuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 313-317 (2011) |
Verlag/Hrsg.: |
Dove Medical Press
|
Schlagwörter: | Neurosciences. Biological psychiatry. Neuropsychiatry / RC321-571 / Neurology. Diseases of the nervous system / RC346-429 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27582317 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doaj.org/article/a6fa6c52e8cd4672a1cdb96a20e5ca86 |